证券代码：600596 证券简称：新安股份 公告编号：2025-046 号 浙江新安化工集团股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 浙江新安化工集团股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十一届董事会第二十次会议、第十一届监事会第十二次会议，审议通过 了《关于部分募集资金投资项目延期的议案》，同意公司对"浙江开化合成材料 有限公司搬迁入园提升项目"整体达到预定可使用状态日期由原计划的 2025 年 实施主体。保荐人中信证券股份有限公司对本事项出具了同意的核查意见。该事 项审批权限在董事会权限范围内，无需提交股东会审议。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意浙江新安化工集团股份有限公司向 特定对象发行股票注册的批复》（证监许可〔2023〕1342 号），公司采用网下向 配售对象询价配售方式，向特定对象发行人民币普通股 203,850,509 股，发行价 为每股人民币 8.83 元，共计募集资金 1,7 ...

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the actual usage of funds by Xinjiang Tianrun Dairy Co., Ltd., emphasizing compliance with regulations and the management of raised funds. Group 1: Fundraising Overview - The company raised a total of RMB 990 million through the issuance of convertible bonds, with a net amount of RMB 979.31 million after deducting issuance costs [1][2] - As of June 30, 2025, the cumulative amount used from the raised funds was RMB 647.87 million, leaving a balance of RMB 334.41 million [1][2] Group 2: Fund Management - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, which was approved by the shareholders' meeting [1][2] - Funds are stored in dedicated accounts, and no non-fund-related deposits have been made [1][2] Group 3: Fund Usage - The company has used RMB 14.05 million from the raised funds in the first half of 2025, with a total of RMB 633.82 million used in previous years [1][2] - The company has replaced self-raised funds with RMB 350.36 million from the raised funds for project investments and issuance costs [2][3] Group 4: Cash Management - The company has approved the use of temporarily idle funds for cash management, with a maximum daily balance of RMB 400 million, and has invested RMB 334.41 million in various financial products [2][3] - The total income from cash management activities during the reporting period was RMB 2.52 million [2][3] Group 5: Project Status - The completion date for the "Annual Production of 200,000 Tons of Dairy Products Processing Project" has been postponed from December 31, 2024, to December 31, 2025, due to construction delays [2][3] - The company has not encountered any significant changes in the feasibility of the projects funded by the raised capital [2][3]

关于发行人股份锁定、减持意向的承诺 是 不适用 关于稳定公司股价的承诺 是 不适用 关于首次公开发行股票并上市招股说明书不存在 是 不适用 虚假记载、误导性陈述或者重大遗漏的承诺函 关于欺诈发行上市的股份回购承诺 是 不适用 关于填补被摊薄即期回报的措施及承诺 是 不适用 关于利润分配政策的承诺 是 不适用 关于规范和减少关联交易的承诺函 是 不适用 关于公司经营管理有关事项的声明承诺函 是 不适用 关于履行公开承诺约束措施的承诺 是 不适用 关于避免同业竞争的承诺函 是 不适用 股东信息披露专项承诺 是 不适用 关于发行申请文件真实性、准确性、完整性的承诺 是 不适用 函 其他承诺 是 不适用 四、其他事项 报告事项 说明 人或者其保荐的公司采取监管措施的事 无 项及整改情况 （本页无正文，为《国信证券股份有限公司关于深圳市菲菱科思通信技术股份有 限公司 2025 年半年度持续督导跟踪报告》之签字盖章页） 保荐代表人： 周 浩 杨家林 国信证券股份有限公司 年 月 日 施 公司及股东承诺事项 原因及解决措 承诺 | 国信证券股份有限公司 | | --- | | 关于深圳市菲菱科思通信技术股份有限公司 | | ...

证券代码：688448 证券简称：磁谷科技 公告编号：2025-029 南京磁谷科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京磁谷科技股份有限公司（以下简称"公司"）第二届董事会第二十四次会 议通知于 2025 年 8 月 5 日通过邮件形式送达公司全体董事，本次会议于 2025 年 8 月 15 日在公司会议室以现场结合通讯的方式召开。本次会议由董事长吴立 华先生召集并主持召开，会议应出席董事 9 人，实际出席董事 9 人，公司监事、 高级管理人员列席会议。 本次会议的召集和召开程序符合《中华人民共和国公司法》《中华人民共和 （以下简称"《公司章程》"） 国证券法》及《南京磁谷科技股份有限公司公司章程》 等有关规定，会议决议合法、有效。 二、董事会会议审议情况 本次会议以记名投票表决方式审议通过如下议案： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 根据《公开发行证券的公司信息披露内容与格式准则第 3 号——半年度报告 的内容与格式》《上海证券交易所 ...

Fundraising Overview - The company raised a total of RMB 70,999,998 from the issuance of 16,888,677 shares at a price of RMB 42.04 per share, with a net amount of RMB 69,705,410 after deducting issuance costs [1] - As of June 30, 2025, the company has invested RMB 52,924,150 of the raised funds, with a remaining balance of RMB 21,349,360 [1][7] Fund Management - The company has established special accounts for the management of raised funds at various banks and signed a tripartite supervision agreement to ensure compliance with regulations [3][5] - The management system for the raised funds was approved by the board and modified by the shareholders' meeting [2] Fund Utilization - The company has utilized RMB 12,121,040 from the raised funds for specific projects, with a total investment of RMB 997,870 during the reporting period [2][6] - The company plans to extend the completion date of the fundraising projects to March 31, 2026, due to external factors affecting project progress [6][8] Financial Performance - The company reported that the cumulative capacity utilization rate of the fundraising projects was below expectations, primarily due to lower-than-expected orders from downstream customers [6] - The company has received small batch orders from leading customers in the optical communication and data center sectors, indicating progress in customer development [6] Cash Management - The company has temporarily used RMB 15,000,000 of idle raised funds to supplement working capital, with RMB 7,300,000 already returned [7][8] - As of June 30, 2025, the company has structured deposits totaling RMB 16,700,000, ensuring high safety and liquidity [7][9]

Meeting Overview - The fifth meeting of the board of directors of Guangdong Deguan Film New Materials Co., Ltd. was held on August 15, 2025, with all 9 directors present [1] - The meeting was conducted in accordance with national laws and regulations [1] Resolutions Passed - The board approved the 2025 semi-annual report and its summary [2] - The board approved the special report on the storage and use of raised funds for the first half of 2025 [2] - The board approved amendments to the company's articles of association and certain governance systems, including the abolition of the supervisory board [2][3] - The board approved the revision of various governance systems, including the rules for shareholder meetings and board meetings [4][5] - The board approved the extension of deadlines for certain fundraising projects, with specific projects now expected to be operational by June 30, 2026, and December 31, 2026, respectively [6] - The board approved a profit distribution proposal from its wholly-owned subsidiary, Guangdong Deguan Packaging Materials Co., Ltd., which plans to distribute 100 million yuan in cash [6] - The board proposed to hold the second extraordinary general meeting of shareholders on September 1, 2025 [7] Documentation - The resolutions and decisions from the meeting will be available for review [8]

Meeting Overview - The fifth meeting of the supervisory board of Guangdong Deguan Film New Materials Co., Ltd. was held on August 15, 2025, in accordance with national laws and regulations [1][2]. Resolutions Passed - The supervisory board approved the "2025 Half-Year Report and Summary" with a unanimous vote of 3 in favor, 0 against, and 0 abstentions [1][2]. - The board also approved the "Special Report on the Storage and Use of Raised Funds for the First Half of 2025," with the same voting results [1][2]. - A resolution was passed regarding the postponement of certain fundraising projects, specifically the "Functional Film and Functional Masterbatch Expansion and Technical Transformation Project" and the "Laboratory and Testing Upgrade Technical Transformation Project." The board confirmed that the postponement would not affect the normal operation of fundraising projects or the company's main business, ensuring no change in the use of raised funds and no harm to the interests of shareholders, especially minority shareholders [2].

Core Viewpoint - The company has decided to postpone the expected operational status dates for certain fundraising projects due to delays in equipment procurement from overseas suppliers, while ensuring that the project implementation subjects, fundraising purposes, and investment amounts remain unchanged [1][4][10]. Fundraising Basic Situation - The company successfully issued 33,333,600 shares at a par value of 1.00 RMB per share, with the total fundraising amount verified by Huaxing Accounting Firm [1]. Fundraising Usage Status - As of June 30, 2025, the total investment amount for the fundraising projects is 108,830.05 million RMB, with an adjusted investment amount of 95,176.21 million RMB, indicating a utilization rate of 84.05% [3][2]. Postponement Details - The postponement affects the "Functional Film and Functional Masterbatch Expansion and Technical Transformation Project" and the "Experimental and Testing Upgrade Technical Transformation Project," with new expected operational status dates set for June 30, 2026, and December 31, 2026, respectively [6][10]. Reasons for Postponement - The delay is primarily due to the long delivery times from overseas equipment suppliers, necessitating a cautious approach to ensure the projects' successful implementation [4][6]. Re-evaluation of Project Feasibility - The company has conducted a re-evaluation of the "Experimental and Testing Upgrade Technical Transformation Project," confirming its necessity and feasibility, which aligns with the company's long-term strategic planning [8][9]. Expected Benefits of Projects - The projects are expected to enhance the company's testing capabilities and improve product quality, thereby supporting long-term development without generating immediate economic benefits [7][8]. Measures for Ensuring Completion - The company plans to allocate uninvested fundraising amounts for foundational construction, equipment procurement, and installation, while closely monitoring project progress to ensure timely completion [9]. Impact of Postponement - The postponement is deemed a prudent decision that does not alter the fundraising project's implementation subjects, purposes, or amounts, and is not expected to adversely affect the company's normal operations [10][11].

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]

Summary of Key Points Core Viewpoint - The company has completed certain fundraising projects and plans to permanently supplement its working capital with the surplus funds while also delaying some fundraising projects [1][9]. Fundraising Overview - The total amount raised from the issuance of shares was approximately RMB 788.55 million, with a net amount of RMB 773.69 million after deducting various fees [1][2]. - The company has established a dedicated account for managing the raised funds and has signed relevant agreements with the sponsor and the bank [2]. Investment Project Details - The total investment for the "Suzhou Technology R&D Center (Phase II) Construction Project" is RMB 113.02 million, with a committed investment of RMB 77.37 million [3]. - The company has approved adjustments to the investment structure and has added a wholly-owned subsidiary as the implementation entity for the "Digital Production Base Construction Project" [3][9]. Fund Usage and Surplus - The completed projects include the "Suzhou Technology R&D Center (Phase II) Construction Project" and the "Information Technology Construction and Intelligent Warehouse Project" [6]. - The surplus funds from these projects will be permanently added to the company's working capital to enhance cash flow and economic efficiency [6][9]. Project Delays - The "Digital Production Base Construction Project" has been delayed, with the expected completion date pushed to March 2026 [7][8]. - The delay is due to stricter site requirements for production processes, necessitating a new implementation location in Changzhou [7][8]. Approval Process - The company's board of directors has approved the conclusion of certain fundraising projects and the use of surplus funds, confirming that these actions will not adversely affect normal operations [9][10]. - The sponsor has verified that the decisions made are in compliance with relevant regulations and will not harm shareholder interests [10].